Background Randomized phase III trials showed interesting, but conflicting results, regarding the treatment of NSCLC, PS2 population. This meta-analysis aims to review all randomized trials comparing platinum-based doublets and single-agents in NSCLC PS2 patients. Materials and methods Data from all published randomized trials, comparing efficacy and safety of platinum-based doublets to single agents in untreated NSCLC, PS2 patients, were collected. Pooled ORs were calculated for the 1-year Survival-Rate (1y-SR), Overall Response Rate (ORR), and grade 3–4 (G3–4) hematologic toxicities. Results Six eligible trials (741 patients) were selected. Pooled analysis showed a significant improvement in ORR (OR: 3.243; 95% CI: 1.883–5.583) and 1y-SR (OR: 1.743; 95% CI: 1.203–2.525) in favor of platinum-based doublets. G3–4 hematological toxicities were also more frequent in this group. Conclusion This meta-analysis suggests that platinum-combination regimens are superior to singleagent both in terms of ORR and survival-rate with increase of severe hematological toxicities.
Bronte, G., Rolfo, C., Passiglia, F., Rizzo, S., Gil-Bazo, I., Fiorentino, E., et al. (2015). What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis. CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY, 95, 306-317 [10.1016/j.critrevonc.2015.03.010].
What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis
BRONTE, Giuseppe;Rolfo, Christian Diego
;PASSIGLIA, Francesco;RIZZO, Sergio;FIORENTINO, Eugenio;CAJOZZO, Massimo;RUSSO, Antonio
2015-01-01
Abstract
Background Randomized phase III trials showed interesting, but conflicting results, regarding the treatment of NSCLC, PS2 population. This meta-analysis aims to review all randomized trials comparing platinum-based doublets and single-agents in NSCLC PS2 patients. Materials and methods Data from all published randomized trials, comparing efficacy and safety of platinum-based doublets to single agents in untreated NSCLC, PS2 patients, were collected. Pooled ORs were calculated for the 1-year Survival-Rate (1y-SR), Overall Response Rate (ORR), and grade 3–4 (G3–4) hematologic toxicities. Results Six eligible trials (741 patients) were selected. Pooled analysis showed a significant improvement in ORR (OR: 3.243; 95% CI: 1.883–5.583) and 1y-SR (OR: 1.743; 95% CI: 1.203–2.525) in favor of platinum-based doublets. G3–4 hematological toxicities were also more frequent in this group. Conclusion This meta-analysis suggests that platinum-combination regimens are superior to singleagent both in terms of ORR and survival-rate with increase of severe hematological toxicities.
| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S1040842815000669-main.pdf
Solo gestori archvio
Tipologia:
Versione Editoriale
Dimensione
867.94 kB
Formato
Adobe PDF
|
867.94 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
